Ítem
Acceso Abierto
Intravitreal bevacizumab in diabetic retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 knobloch lecture
Título de la revista
Autores
Arevalo J.F.
Liu T.Y.A.
Wu L.
Lasave A.F.
Farah M.
Maia M.
Penha F.M.
Rodrigues E.B.
Morales-Canton V.
Fromow-Guerra J.
Archivos
Fecha
2018
Directores
ISSN de la revista
Título del volumen
Editor
Asia-Pacific Academy of Ophthalmology
Citations
Métricas alternativas
Resumen
Abstract
The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy. Copyright © 2017 by Asia Pacific Academy of Ophthalmology.
Palabras clave
Keywords
Angiogenesis inhibitor , Bevacizumab , Adjuvant chemotherapy , Diabetic retinopathy , Human , Intravitreal drug administration , Macular edema , Preoperative care , Angiogenesis inhibitors , Bevacizumab , Chemotherapy , Diabetic retinopathy , Humans , Intravitreal injections , Macular edema , Preoperative care , Bevacizumab , Diabetic macular edema , Intravitreal injections , Proliferative diabetic retinopathy , Tractional retinal detachment
